ATE523082T1 - Verwendung von somatostatin-agonisten zur behandlung von medullärem schilddrüsenkarzinom - Google Patents

Verwendung von somatostatin-agonisten zur behandlung von medullärem schilddrüsenkarzinom

Info

Publication number
ATE523082T1
ATE523082T1 AT07753923T AT07753923T ATE523082T1 AT E523082 T1 ATE523082 T1 AT E523082T1 AT 07753923 T AT07753923 T AT 07753923T AT 07753923 T AT07753923 T AT 07753923T AT E523082 T1 ATE523082 T1 AT E523082T1
Authority
AT
Austria
Prior art keywords
thyroid carcinoma
medullary thyroid
treatment
somatostatin agonists
carcinoma cells
Prior art date
Application number
AT07753923T
Other languages
English (en)
Inventor
Maria Zatelli
Michael Culler
Uberti Ettore Degli
Original Assignee
Ipsen Pharma
Univ Ferrara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma, Univ Ferrara filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE523082T1 publication Critical patent/ATE523082T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07753923T 2006-03-23 2007-03-23 Verwendung von somatostatin-agonisten zur behandlung von medullärem schilddrüsenkarzinom ATE523082T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78539906P 2006-03-23 2006-03-23
US78507706P 2006-03-23 2006-03-23
US78681406P 2006-03-28 2006-03-28
PCT/US2007/007339 WO2007112045A2 (en) 2006-03-23 2007-03-23 Use of somatostatin agonists to treat medullary thyroid carcinoma

Publications (1)

Publication Number Publication Date
ATE523082T1 true ATE523082T1 (de) 2011-09-15

Family

ID=38541707

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07753923T ATE523082T1 (de) 2006-03-23 2007-03-23 Verwendung von somatostatin-agonisten zur behandlung von medullärem schilddrüsenkarzinom

Country Status (4)

Country Link
US (1) US20090099094A1 (de)
EP (1) EP2003967B1 (de)
AT (1) ATE523082T1 (de)
WO (1) WO2007112045A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2709140C1 (ru) * 2018-12-10 2019-12-16 Евгений Викторович Рябченко Способ дооперационного определения объема хирургического лечения высокодифференцированного рака щитовидной железы

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2743731C (en) * 2001-03-06 2014-05-06 The Administrators Of The Tulane Educational Fund Method of modulating the proliferation of medullary thyroid carcinoma cells

Also Published As

Publication number Publication date
EP2003967B1 (de) 2011-09-07
EP2003967A2 (de) 2008-12-24
WO2007112045A3 (en) 2008-10-16
EP2003967A4 (de) 2009-08-19
US20090099094A1 (en) 2009-04-16
WO2007112045A2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
TW200642695A (en) Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
WO2009025806A3 (en) Use of vegfr-2 inhibitors for treating metastatic cancer
EA200970729A1 (ru) Варианты, происходящие из actriib, и их применение
WO2011022489A3 (en) (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
EP2575884A4 (de) Anwendungen und zusammensetzungen zur behandlung von acne inversa
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CL2011002690A1 (es) Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis.
EA200700648A1 (ru) 4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги
MX2009000359A (es) Metodos paratratar y limitar trastornos fibroticos y queloides.
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
EA200700647A1 (ru) 4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги
EA201290718A1 (ru) Применение ингибиторов сукцинат-дегидрогеназы (sdh) для обработки видов растений из семейства мятликовых злаков
ATE526953T1 (de) Verwendung von 5-ht7-rezeptor-agonisten zur behandlung von schmerzen
MX2012001999A (es) Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2.
ATE410235T1 (de) Behandlung von ballastwasser
ATE523082T1 (de) Verwendung von somatostatin-agonisten zur behandlung von medullärem schilddrüsenkarzinom
TNSN08395A1 (en) Use of calcium carbonate as technological coadjuvant in oil and fat extraction processes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties